Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-27

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Lorundrostat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 247,857Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mineralys Completes Enrollment in Lorundrostat Hypertension Trial
    Mineralys Completes Enrollment in Lorundrostat Hypertension Trial

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971654/0/en/Mineralys-Therapeutics-Completes-Enrollment-Ahead-of-Schedule-in-Launch-HTN-the-Second-Pivotal-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Mineralys Therapeutics Completes Enrollment In Advance-HTN Trial
    Mineralys Therapeutics Completes Enrollment In Advance-HTN Trial

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952886/0/en/Mineralys-Therapeutics-Completes-Target-Enrollment-in-Pivotal-Advance-HTN-Trial-of-Lorundrostat-for-the-Treatment-of-Hypertension.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Mineralys Presents Post-Hoc Analysis from Target-HTN Phase 2 of Lorundrostat
    Mineralys Presents Post-Hoc Analysis from Target-HTN Phase 2 of Lorundrostat

    02 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/02/2772515/0/en/Mineralys-Therapeutics-Presents-New-Post-Hoc-Analysis-from-Target-HTN-Phase-2-Trial-of-Lorundrostat-in-Late-Breaking-Poster-Session-at-ASN-Kidney-Week-2023-Meeting.html

    GLOBENEWSWIRE
    02 Nov 2023
    Share Share
    Mineralys Announces Expansion of Planned Phase 2 Trial of Lorundrostat
    Mineralys Announces Expansion of Planned Phase 2 Trial of Lorundrostat

    17 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/17/2705962/0/en/Mineralys-Therapeutics-Announces-Expansion-of-Planned-Phase-2-Trial-of-Lorundrostat-Alone-and-in-Combination-with-SGLT2-Inhibitor-to-Treat-Patients-with-Chronic-Kidney-Disease-CKD.html

    GLOBENEWSWIRE
    17 Jul 2023
    Share Share
    Mineralys Announces First Patient Dosed the ADVANCE-HTN Trial of Lorundrostat
    Mineralys Announces First Patient Dosed the ADVANCE-HTN Trial of Lorundrostat

    02 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/02/2659083/0/en/Mineralys-Therapeutics-Announces-First-Patient-Dosed-in-the-ADVANCE-HTN-Pivotal-Trial-of-Lorundrostat-for-the-Treatment-of-Uncontrolled-and-Resistant-Hypertension.html

    GLOBENEWSWIRE
    02 May 2023
    Share Share
    Mineralys Presents Positive Lorundrostat Results from Phase 2 Target-HTN Trial
    Mineralys Presents Positive Lorundrostat Results from Phase 2 Target-HTN Trial

    04 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/04/2620621/0/en/Mineralys-Therapeutics-Presents-Positive-Lorundrostat-Results-from-the-Phase-2-Target-HTN-Trial-at-ACC-23-WCC.html

    GLOBENEWSWIRE
    04 Mar 2023
    Share Share